JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in CD𝟖⁺ T Cells in Renal Cell Carcinoma Patients

Figure 1

IFN-𝛾 Elispot Assay CD8⁺ T cells isolated at day 0. RCC1 cell line as stimulator cells and CD8⁺ T cells isolated from PBMC of RCC1-patient (a) and their allogeneic donor-1a (b) and donor-1b (c) at day 0 were tested in 20 h IFN-𝛾-Elispot Assay. HLA restriction of anti-RCC reactivity was determined by adding mAbs specific for total HLA-class I and HLA-DR. Results represent the average (± SD) of triplicate wells and the presented data derive from 1 representative experiment of 5 performed. A paired 𝑡-test analysis was used to compare the frequencies of autologous versus allogenic specific CD8⁺ T cells stimulated with RCC1 cell line, after subtraction of HLA class I reactivity; 𝑃<.03 was considered statistically significant (*).

(a)

(b)

(c)